Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 33 results:
[ Συντάκτης(Desc)] Τίτλος Τύπος Έτος
Φίλτρα: Keyword is Pyrroles  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Anagnostis, P., Selalmatzidou D., Polyzos S. A., Panagiotou A., Slavakis A., Panagiotidou A., et al. (2011).  Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study.. Int J Clin Pract. 65(6), 679-83.
Anagnostis, P., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2011).  Impact of statins on glucose metabolism--a matter of debate.. Am J Cardiol. 107(12), 1866.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2014).  Are statins 'IDEAL' for non-alcoholic fatty liver disease?. Curr Med Res Opin. 30(2), 229-31.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2010).  Atorvastatin: safety and tolerability.. Expert Opin Drug Saf. 9(4), 667-74.
Athyros, V. G., Mikhailidis D. P., Liberopoulos E. N., Kakafika A. I., Karagiannis A., Papageorgiou A. A., et al. (2007).  Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with CHD and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study.. Nephrol Dial Transplant. 22(1), 118-27.
Athyros, V. G., Elisaf M. S., Alexandrides T., Achimastos A., Ganotakis E., Bilianou E., et al. (2012).  Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis.. Angiology. 63(5), 358-66.
Athyros, V. G., Tziomalos K., Karagiannis A., Wierzbicki A. S., & Mikhailidis D. P. (2010).  Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?. Curr Opin Cardiol. 25(4), 406-10.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2013).  Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property".. Dig Liver Dis. 45(1), 82-3.
Athyros, V. G., Mikhailidis D. P., Didangelos T. P., Giouleme O. I., Liberopoulos E. N., Karagiannis A., et al. (2006).  Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.. Curr Med Res Opin. 22(5), 873-83.
Athyros, V. G., Kakafika A. I., Papageorgiou A. A., Paraskevas K. I., Tziomalos K., Anagnostis P., et al. (2008).  Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study.. Curr Med Res Opin. 24(6), 1593-9.
Athyros, V. G., Mikhailidis D. P., Papageorgiou A. A., Didangelos T. P., Peletidou A., Kleta D., et al. (2005).  Targeting vascular risk in patients with metabolic syndrome but without diabetes.. Metabolism. 54(8), 1065-74.
Athyros, V. G., Karagiannis A., Ganotakis E. S., Paletas K., Nicolaou V., Bacharoudis G., et al. (2011).  Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study.. Curr Med Res Opin. 27(8), 1659-68.
Athyros, V. G., Tziomalos K., Kakafika A. I., Koumaras H., Karagiannis A., & Mikhailidis D. P. (2008).  Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients.. Am J Cardiol. 101(4), 483-5.
Athyros, V. G., Karagiannis A., Katsiki N., & Mikhailidis D. P. (2012).  Relation of improvement in glomerular filtration rate with atorvastatin to reductions in heart failure morbidity.. Am J Cardiol. 110(5), 763.
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Cardiovascular risk reduction with combination of anti-atherosclerotic medications in younger and older patients.. Curr Med Res Opin. 29(7), 791-2.
Athyros, V. G., Kakafika A. I., Papageorgiou A. A., Tziomalos K., Skaperdas A., Pagourelias E., et al. (2007).  Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients.. Lipids. 42(11), 999-1009.
B
Bamias, A., Karadimou A., Lampaki S., Lainakis G., Malettou L., Timotheadou E., et al. (2010).  Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model.. BMC Cancer. 10, 45.
Bamias, A., Tzannis K., Beuselinck B., Oudard S., Escudier B., Diosynopoulos D., et al. (2013).  Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration.. Br J Cancer. 109(2), 332-41.
C
Crown, J. P., Diéras V., Staroslawska E., Yardley D. A., Bachelot T., Davidson N., et al. (2013).  Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.. J Clin Oncol. 31(23), 2870-8.
E
Escudier, B., Roigas J., Gillessen S., Harmenberg U., Srinivas S., Mulder S. F., et al. (2009).  Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.. J Clin Oncol. 27(25), 4068-75.
F
Fountzilas, G., Fragkoulidi A., Kalogera-Fountzila A., Nikolaidou M., Bobos M., Calderaro J., et al. (2010).  A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer.. Cancer Chemother Pharmacol. 65(4), 649-60.
G
Goulas, A., Kosmidou M., Hatzitolios A. I., Molyva D., Fidani L., Giannopoulos S., et al. (2008).  Glutathione S-transferase null and cholesteryl ester transfer protein TaqI B polymorphisms and lipid response to atorvastatin in Greek dyslipidaemic patients.. Basic Clin Pharmacol Toxicol. 102(6), 559-62.
K
Kadoglou, N. P. E., Sailer N., Moumtzouoglou A., Kapelouzou A., Gerasimidis T., Kostakis A., et al. (2012).  Adipokines: a novel link between adiposity and carotid plaque vulnerability.. Eur J Clin Invest. 42(12), 1278-86.
Kadoglou, N. P. E., Gerasimidis T., Kapelouzou A., Moumtzouoglou A., Avgerinos E. D., Kakisis J. D., et al. (2010).  Beneficial changes of serum calcification markers and contralateral carotid plaques echogenicity after combined carotid artery stenting plus intensive lipid-lowering therapy in patients with bilateral carotid stenosis.. Eur J Vasc Endovasc Surg. 39(3), 258-65.
Kadoglou, N. P. E., Sailer N., Moumtzouoglou A., Kapelouzou A., Gerasimidis T., & Liapis C. D. (2010).  Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization.. J Vasc Surg. 51(1), 114-21.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές